This page is free to read, and it stops after 2 rows. Everything we currently hold fits inside that, so nothing is being held back here today. Reading the whole list, and what each filing says: its issues, the agencies contacted and the lobbyists named, is part of the subscription. So is sorting the list by the reported amount. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
Lobbying reported per quarter
reported amounts per quarter, latest version of each report
Reported income: what lobbying firms reported receiving from this company's clients, per quarter.
Reported income
Recent activity
Register facts only. Everything on this page comes from filings made under the Lobbying Disclosure Act of 1995 and kept by the Secretary of the Senate. We read the filings, we link a client to a listed company where a reviewed rule allows it, and we add nothing else. No score, no ranking and no judgement is attached to lobbying on this site. See the methodology and about this site.
| Registrant | Filing | Amount | Posted | Source | Registrant | Amount | Filing | All amounts | Posted | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| JEFFREY J. KIMBELL & ASSOCIATES, INC.for PHATHOM PHARMACEUTICALS | 1st Quarter - Report1st Quarter 2025 | $15,000incomeposted Apr 21, 2025 | Apr 21, 2025 | LD-2 at lda.gov | JEFFREY J. KIMBELL & ASSOCIATES, INC.for PHATHOM PHARMACEUTICALS | $15,000 | 1st Quarter - Report1st Quarter 2025 | $15,000income | Apr 21, 2025 | LD-2 at lda.gov |
| JEFFREY J. KIMBELL & ASSOCIATES, INC.for PHATHOM PHARMACEUTICALS | Registration1st Quarter 2025 | no amountregistrationposted Apr 20, 2025 | Apr 20, 2025 | LD-2 at lda.gov | JEFFREY J. KIMBELL & ASSOCIATES, INC.for PHATHOM PHARMACEUTICALS | no amount | Registration1st Quarter 2025 | no amountregistration | Apr 20, 2025 | LD-2 at lda.gov |
The link between the client names above and PHAT is a reviewed rule of ours, not something the filing states: an LD-2 names a client and carries no ticker, no CIK and no LEI.